Cutting-edge trends on regenerative therapy: Induced embryonic and pluripotential stem cells, angiogenic growth factor and gene therapy

Authors

  • José R. Hidalgo Díaz
  • Juan C. Chachques
  • Ángel Paredes Cordero

Abstract

Cutting-edge trends on regenerative therapy: Induced embryonic and pluripotential stem cells, angiogenic growth factor and gene therapy

Downloads

Download data is not yet available.

References

1. Hidalgo Díaz J. Las células madre y sus debates: nociones muy básicas. ContraPunto [Internet]. 2019 [citado 18 Dic 2018]. Disponible en: https://www.contrapunto.com.sv/opinion/academia/las-celulas-madre-y-sus-debates-nociones-muy-basicas/9257

2. Johnson MH, Cohen J. Reprogramming rewarded: the 2012 Nobel prize for Physiology or Medicine awarded to John Gurdon and Shinya Yamanaka. Reprod Biomed Online. 2012;25(6):549-50.

3. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-84.

4. Hidalgo Díaz J. Las células madre y sus debates: nociones muy básicas para no entendidos. Temas [Internet] 2017 [citado 18 Dic 2018]. Disponible en: http://www.temas.cult.cu/catalejo/las-c-lulas-madre-y-sus-debates-nociones-muy-b-sicas-para-no-entendidos

5. Feldman DE, Chen C, Punj V, Tsukamoto H, Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A. 2012;109(3):829-34.

6. Hernández Cañero A, Hidalgo Díaz J. La regeneración del corazón y la terapia celular con células madre. Rev CENIC Ciencias Biol. 2004;35(3):210-11.

7. Hidalgo Díaz JR, Hernández Cañero A, Chachques JC, Paredes Cordero A. Células madre mesenquimales de médula ósea y de cordón umbilical en el tratamiento de enfermedades cardiovasculares. CorSalud [Internet]. 2018 [citado 20 Dic 2018];10(1):47-51. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/294/628

8. Chachques JC, Duarte F, Cattadori B, Shafy A, Lila N, Chatellier G, et al. Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study. J Thorac Cardiovasc Surg. 2004;128(2):245-53.

9. Gálvez-Montón C, Prat-Vidal C, Roura S, Soler-Botija C, Bayes-Genis A. Ingeniería tisular cardiaca y corazón bioartificial. Rev Esp Cardiol. 2013;66(5):391-9.

10. Nadal-Ginard B. Inducción de nuevos cardiomiocitos en el corazón adulto: futuro de la regeneración miocárdica como alternativa al trasplante. Rev Esp Cardiol. 2001;54(5):543-50.

11. Jhala D, Rather H, Kedaria D, Shah J, Singh S, Vasita R. Biomimetic polycaprolactone-chitosan nanofibrous substrate influenced cell cycle and ECM secretion affect cellular uptake of nanoclusters. Bioact Mater. 2018;4(1):79-86.

12. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Mesquita CT, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107(18):2294-302.

13. Chachques JC, Hidalgo J, Cattadori B, Duarte F, Shafy A, Argyriadis P, et al. Cardiomioplastia Celular: Un nuevo enfoque terapéutico para la disfunción ventricular. Cardiología Intercontinental. 2001;10(1):11-5.

14. Mathison M, Gersch RP, Nasser A, Lilo S, Korman M, Fourman M, et al. In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular endothelial growth factor. J Am Heart Assoc [Internet]. 2012 [citado 20 Dic 2018];1(6):e005652. Disponible en: https://www.ahajournals.org/doi/pdf/10.1161/JAHA.112.005652

Downloads

Published

2019-10-28

How to Cite

1.
Hidalgo Díaz JR, Chachques JC, Paredes Cordero Ángel. Cutting-edge trends on regenerative therapy: Induced embryonic and pluripotential stem cells, angiogenic growth factor and gene therapy. CorSalud [Internet]. 2019 Oct. 28 [cited 2025 Jun. 22];11(4):302-6. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/559

Issue

Vol. 11 No. 4 (2019)

Section

SPECIAL ARTICLES

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.